/
ELOX
$11.93-$0.12 (-0.95%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$41.4M
3M shares
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
58.38%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-868.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $93.4K | $39.0K | $216.0K | $559.0K | $571.0K | $960.0K | $695.0K | $0 |
| Gross profit | −$18.4K | −$39.0K | −$216.0K | −$559.0K | −$571.0K | −$960.0K | −$695.0K | $0 |
| Gross margin | -24.5% | — | — | — | — | — | — | — |
| R&D | $2.1M | $16.4M | $20.5M | $25.8M | $14.6M | $22.9M | $23.7M | $3.1M |
| Operating income | −$3.7M | −$20.4M | −$47.0M | −$50.6M | −$29.4M | −$42.3M | −$34.4M | −$6.4M |
| EBITDA | −$3.6M | −$20.4M | −$46.8M | −$50.0M | −$28.9M | −$64.5M | −$33.5M | −$4.9M |
| Net income | −$8.3M | −$21.2M | −$47.2M | −$50.9M | −$34.6M | −$66.7M | −$36.1M | −$6.0M |
| Net margin | -11023.9% | — | — | — | — | — | — | — |
| EPS (diluted) | -3696.00 | -2090.00 | -640.09 | -588.06 | -379.17 | -419.65 | -183.15 | -5.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-8.04 | $-8.04–$-8.04 | 1 |
| 2027 | $174M | $13.52 | $13.52–$13.52 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.22
Price
$11.93
Implied downside
-90%
Peer comparison
Eloxx Pharmaceuticals, Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
www.eloxxpharma.com- Employees
- 7
- IPO / List date
- Dec 11, 1998
- HQ
- ARLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds ELOX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ELOX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-01 | 1-for-11reverse |
| 2022-12-02 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded ELOX yet.
